comparemela.com
Home
Live Updates
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer : comparemela.com
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 -- eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,...
Related Keywords
United States ,
Panagiotis Konstantinopoulos ,
Michael Fitzhugh ,
Christopherm Calabrese ,
Kevin Gardner ,
Doug Warner ,
Lifesci Communications ,
Nasdaq ,
Professor Of Medicine At Harvard Medical School ,
Dana Farber Cancer Institute ,
Exchange Commission ,
Pfizer ,
Effector Therapeutics Inc ,
Translational Research ,
Division Of Gynecologic Oncology ,
Gynecologic Oncology ,
Associate Professor ,
Harvard Medical ,
Private Securities Litigation Reform Act ,
comparemela.com © 2020. All Rights Reserved.